Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

NCT07302802 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a weekly injection of semaglutide can help adolescents with monogenic obesity lose weight over 68 weeks.

Status Recruiting Currently enrolling participants.

Type Observational

Participants 70 people Planned (estimated).

Who can join Ages 12–21 · all sexes

Timeline Started 2025-12 · est. completion 2028-12

Where 7 sites · France, Germany, Netherlands, Spain, United Kingdom

What this study is testing ClinicalTrials.gov NCT07302802 ↗

Description as written by the study sponsor.

This observational study aims to assess the effect of once-weekly s.c. semaglutide 2.4 mg as an adjunct to a calorie-reduced diet and increased physical activity on weight loss, change in hunger, body composition, depression, and quality of life after 68 weeks of treatment in adolescents diagnosed with monogenic obesity in routine clinical care.

Treatments tested

Semaglutide (administered by PDS290 pen-injector) Drug

Treatment with semaglutide as prescribed in routine clinical practice according to summary of product characteristics. The use of semaglutide can be categorised into two groups during enrolment period: 1. new users, or 2. current users (e.g., those continuing semaglutide treatment prescribed in routine clinical practice).

Main thing measured	Proportion of participants achieving ≥10% BMI reduction from baseline (week 0) to week 68.
Sponsor	Prof. Dr. Martin Wabitsch
Conditions studied	Monogenic Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07302802 ↗